Valo Health

Flagship-built AI drug-discovery company (Opal platform); lost its clinical assets in 2024 and now runs mostly on Novo Nordisk and Merck KGaA deals.

1. Core Product / Service

Valo was incorporated in October 2018 as Flagship Labs 61 and launched in 2019 [1]. Its Opal platform links large de-identified longitudinal patient datasets with genomics, which it describes as "AI-enabled human causal biology", to choose targets. Molecules are then designed and made through "closed-loop chemistry" built on DNA-encoded libraries and automated screening, and targets are validated in 3D engineered human tissue models [1][4][5]. The 2021 SPAC filing claimed more than 30,000 predictive models [1].

Its clinical assets were in-licensed from Sanofi, and the filing states they "were not developed using the Opal Platform" [1]. OPL-0401 (ROCK1/2, diabetic retinopathy) missed its Phase 2 endpoints in Dec 2024, and internal development was suspended [3]. OPL-0301 (S1P1) was withdrawn before enrolment. As of 2026 Valo discloses no internal clinical-stage asset; its work is preclinical discovery, much of it with partners [3].

Wet lab. The 2021 filing described "real-world lab capability with more than 40,000 square feet": a DNA-encoded library of over 5 billion compounds, four automated high-throughput screening platforms, automated synthesis, and a 500,000-compound HTS library [1]. Leases totalled ~29,000 sf in Lexington, MA and ~27,000 sf in Branford, CT [1]. Much of this came from acquiring Forma Therapeutics' early-discovery unit in 2020, including 23 staff and the Branford lab [1]. In 2022 Valo bought TARA Biosystems (New York) for engineered human heart-tissue models [5]. In 2021 headcount was 173, with 127 in R&D (66 in AI/engineering/product) [1]. Current figures are not disclosed. GMP manufacturing is "completely dependent on … contract manufacturers", clinical and nonclinical work uses CROs [1], and Charles River provides HTS and preclinical services under the 2025 Logica collaboration.

2. Target Users & Pain Points

• Pharma partners: Novo Nordisk (cardiometabolic; expanded 2025) and Merck KGaA (Parkinson's; Nov 2025) license Opal-derived programmes [4].
• Pain addressed: target choice drives most late-stage failure, and Valo's bet is that human longitudinal data plus causal ML picks better targets than animal models.

3. Competitive Landscape

4. Unique Observations

• The clinical failures did not test the platform. Both clinical assets were in-licensed and pre-dated Opal, so the 2024 Phase 2 miss says little about the AI platform itself [1][3].
• The pivot to partnering was large. After losing its clinical pipeline, Valo signed Novo's expanded deal ($190M upfront, equity and near-term milestone; ~$4.6B in potential milestones across up to 20 programmes) and a Merck KGaA deal worth "up to over $3 billion" [4]. Its economics now look closer to a platform partner than a pipeline company.
• A 2021 SPAC that never closed. The Khosla Ventures Acquisition Co. deal valued Valo at $2.0B pre-money with a $200.9M PIPE. It was terminated in November 2021 [1][2], so Valo stayed private through the downturn.

5. Financials / Funding

• Series A ~$96M (2019–20, Flagship); Series B ~$300M (Dec 2020–Feb 2021, incl. a $110M Koch extension; Koch Disruptive Technologies, PSP) [1][6].
• Novo Nordisk equity in 2025 as part of a $190M package; the equity amount is not split out [4].
• Cumulative equity ≈ $400M+. Aggregators range from $400M to $520M, and the higher figures cite an unverified Series C.
• Novo deal (2023): $60M upfront plus a near-term milestone; up to $2.7B in milestones [4].

6. People & Relationships

• Founding CEO: David Berry (Flagship), left Feb 2024.
• CEO: Brian Alexander (since Nov 2024; ex-Foundation Medicine CEO, ex-Roche/Genentech).
• CSO: Karin Conde-Knape (since 2026; ex-Novo Nordisk). Chief Causal AI Officer: Chris Anagnostopoulos (since 2026).
• Parent / investors: Flagship Pioneering, Koch Disruptive Technologies, PSP Investments. Partners: Novo Nordisk, Merck KGaA, Charles River, nference. Sibling: lila-sciences.

Sources

• [1] Khosla Ventures Acquisition Co. / Valo Health proxy statement-prospectus (424B3, Oct 2021), SEC EDGAR (2026-10-14)
• [2] Khosla Ventures Acquisition Co. 8-K, termination of Valo merger (Nov 2021), SEC EDGAR (2026-10-14)
• [3] Valo Health, OPL-0401 Phase 2 SPECTRA topline results (2026-10-14)
• [4] Valo Health, expanded Novo Nordisk collaboration (Jan 2025; accessed 2026-10-14)
• [5] Valo Health, acquisition of TARA Biosystems (2026-10-14)
• [6] Fierce Biotech, "Valo Health grabs $110M top-up" (2026-10-14)